#1G A G A G A G A T Ĉ A T G A T G G A G G G A T A A A T T G G G A G Jea 23andMe Investor Presentation February 2022 A A C G G G A C C C G G C C C C G A T G A G A G G C C T A T T C A A G G A G C#2Disclaimer Forward-Looking Statements This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding the future performance of 23andMe's businesses in consumer genetics and therapeutics and the growth and potential of its proprietary research platform. All statements, other than statements of historical fact, included or incorporated in this presentation, including statements regarding 23and Me's strategy, financial position, funding for continued operations, cash reserves, projected costs, plans, and objectives of management, are forward-looking statements. The words "believes," "anticipates," "estimates," "plans," "expects," "intends," "may," "could," "should," "potential," "likely," "projects," "continue," "will," "schedule," and "would" or, in each case, their negative or other variations or comparable terminology, are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements are predictions based on 23andMe's current expectations and projections about future events and various assumptions. 23andMe cannot guarantee that it will actually achieve the plans, intentions, or expectations disclosed in its forward-looking statements and you should not place undue reliance on 23andMe's forward-looking statements. These forward-looking statements involve a number of risks, uncertainties (many of which are beyond the control of 23and Me), or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. The forward-looking statements contained herein are also 8-K filed with the Securities and Exchange Commission ("SEC") on June 21, 2021 and in 23andMe's Current Report on Form 10-Q filed with the SEC on February 11, 2022 as well as other filings made by 23andMe with the SEC from time to time. Investors are cautioned not to place undue reliance on any such forward-looking statements, which speak only as of the date they are made. Except as required by law, 23andMe does not undertake any obligation to update or revise any forward-looking statements whether as a result of new information, future events, or otherwise. Use of Non-GAAP Financial Measures To supplement the 23andMe's unaudited condensed consolidated statements of operations and unaudited condensed consolidated balance sheets, which are prepared in conformity with generally accepted accounting principles in the United States of America ("GAAP"), this presentation also includes references to Adjusted EBITDA, which is a non-GAAP financial measure that 23andMe defines as net income before net interest expense (income), net other expense (income), changes in fair value of warrant liabilities, depreciation and amortization of fixed assets, amortization of internal use software, non-cash stock-based compensation expense, acquisition-related costs, and expenses related to restructuring and other charges, if applicable for the period. 23andMe has provided a reconciliation of net loss, the most directly comparable GAAP financial measure, to Adjusted EBITDA at the end of this presentation. Adjusted EBITDA is a key measure used by 23andMe's management and the board of directors to understand and evaluate operating performance and trends, to prepare and approve 23andMe's annual budget and to develop short- and long-term operating plans. 23andMe provides Adjusted EBITDA because 23andMe believes it is frequently used by analysts, investors and other interested parties to evaluate companies in its industry and it facilitates comparisons on a consistent basis across reporting periods. Further, 23andMe believes it is helpful in highlighting trends in its operating results because it excludes items that are not indicative of 23andMe's core operating performance. In particular, 23andMe believes that the exclusion of the items eliminated in calculating Adjusted EBITDA provides useful measures for period-to-period comparisons of 23andMe's business. Accordingly, 23andMe believes that Adjusted EBITDA provides useful information in understanding and evaluating operating results in the same manner as 23andMe's management and board of directors. In evaluating Adjusted EBITDA, you should be aware that in the future 23andMe will incur expenses similar to the adjustments in this presentation. 23andMe's presentation of Adjusted EBITDA should not be construed as an inference that future results will be unaffected by these expenses or any unusual or non-recurring items. Adjusted EBITDA should not be considered in isolation of, or as an alternative to, measures prepared in accordance with GAAP. Other companies, including companies in the same industry, may calculate similarly-titled non-GAAP financial measures differently or may use other measures to evaluate their performance, all of which could reduce the usefulness of Adjusted EBITDA as a tool for comparison. There are a number of limitations related to the use of these non-GAAP financial measures rather than net loss, which is the most directly comparable financial measure calculated in accordance with GAAP. Some of the limitations of Adjusted EBITDA include (i) Adjusted EBITDA does not properly reflect capital commitments to be paid in the future, and (ii) although depreciation and amortization are non-cash charges, the underlying assets may need to be replaced and Adjusted EBITDA does not reflect these capital expenditures. When evaluating 23andMe's performance, you should consider Adjusted EBITDA alongside other financial performance measures, including net loss and other GAAP results. Intellectual Property All rights to the trademarks, copyrights, logos and other intellectual property listed herein belong to their respective owners 23andMe's use thereof does not imply an affiliation with, or endorsement by the owners of such trademarks, copyrights, logos and other intellectual property. Solely for convenience, trademarks and trade names referred to in this Presentation may appear with the Ⓡor TM symbols, but such references are not intended to indicate, in any way, that such names and logos are trademarks or registered trademarks of 23andMe. Industry and Market Data This Presentation relies on and refers to certain information and statistics based on 23andMe's management's estimates, and/or obtained from third party sources which it believes to be reliable. 23andMe has not independently verified the accuracy or completeness of any such third party information. Copyright © 2022 23and Me, Inc. 23andMe 2#3G G Behind Every Data Point Is A Human Being T T с T C C с G#4Our Mission is to Help People Access, Understand, and Benefit from the Human Genome H 23andMe 1 As of December 31, 2021. Welcome to you saliva collection kit 23andMe REGENERON MILLION VETERAN PROGRAM UK BIOBANK DECODE GENETICS ALL OF US FINNGEN GENOMICS ENGLAND 825,000 1.6M 500,000 500,000 366,000 219,000 100,000 Size and scale of 23andMe enables rapid, novel discoveries Copyright © 2022 23and Me, Inc. 23andMe 12.2M¹ 4#5The Healthcare System is Dysfunctional "Of course our system isn't about healthcare, it's about maximizing revenue for a whole bunch of different players that have nothing to do with what's good for patients." Elisabeth Rosenthal (Editor-in-Chief, Kaiser Health News) 1 JAMA, "Waste in the US Health Care System" (2019). 2 Redpoint Global / Dynata survey of over 1,000 U.S. consumers (2020). 3 Gallup, "Americans' Views of U.S. Business and Industry Sectors" (2020). 4 PhRMA, "Biopharmaceutical Research & Development: The Process Behind New Medicines" (2015). 25%¹ U.S. healthcare spending is waste 2 75% Consumers wish their healthcare experience was more personalized -15³ The net positive score Americans gave the pharmaceutical industry <12%* Probability of success for a drug to be approved, taking ~10 years and costing $2.6B to develop Copyright © 2022 23and Me, Inc. 23and Me 5#6Media Commerce Hospitality >>> Healthcare Transportation >>> Uber >>> amazon ► YouTube >>> >> airbnb X 23andMe Consumer Scale and Empowerment is the Key to Disrupting Healthcare "Healthcare cannot change from within, it will need an outside force to change it, and that force will be our customers." Anne Wojcicki#7We Pioneered Digital DTC Healthcare to Empower Customers With Affordable, Direct Access ¹ See FDA De Novo Authorizations 140044, 160026, 170046 and 180028 and FDA 510K Clearances K182784 and K193492. TIME MAGAZINE INVENTION OF THE YEAR 1. The Retail DNA Test By Anita Hamilton I Wednesday, Oct. 29, 2008 Best Inventions of 2008 > From a genetic testing service to an invisibility cloak to an ingenious public bike system to the world's first moving skyscraper - here are TIME's picks for the top innovations of 2008 7 FDA Proven accuracy (99% NPV/PPV) and accessibility¹ Authorizations. 2015 2016 2017 2019 2020 Carrier Status (inherited conditions) 2018 PGt (pharmacogenetic metabolism) 2021 GHR (genetic health risk) BRCA (breast and ovarian cancer) MUTYH (colorectal cancer) PGt (pharmacogenetic drug response) HOXB13 (prostate cancer)#880% Customers receive a report with a meaningful genetic variant 7,000+ Customers with a tested BRCA1 / BRCA2 variant 12,000+ Customers with an increased risk for Chronic Kidney Disease 9,000+ Customers with Hypercholesterolemia (FH) variants Note: Estimates based on penetrance of variants in 23andMe's Database as of March 31, 2021. Providing Customers With Key, Actionable Insights "Like me, there are many women who have slipped through the cracks of our current medical screening system, either because they don't have a family history of breast or ovarian cancer. Or they do not know that they have Ashkenazi Jewish ancestry. In my case, even though I know I have Ashkenazi ancestry, that wasn't enough to prompt my doctor to consider screening. So there are many women walking around with this risk, who, like me, would have never known of their own risk but for this test from 23andMe." 23andMe customer who discovered she had a BRCA1 mutation#9G 2 Transforming Healthcare With 23andMe's Crowdsourced, Genetic Database T G "The mission of 23andMe is not just about genetics. We want to transform healthcare... What I have learned after 11 years is that people want to participate in research... They don't want to be G G a human subject. They want to be respected as an equal and as a partner in the process.” “ Anne Wojcicki to Recode Decode (2018) T C C G#10A G Unlocking the Genetic Code Creates the Opportunity to the Revolutionize Diagnosis, Prevention and Treatment of Most, if Not All, Human Disease T T C € Cracking the code... ACGT ...is a data problem, a very big data problem We are all 99.5% genetically alike 3 billion base pairs long Copyright © 2022 23and Me, Inc. 23and Me 10#11We Are Redefining Healthcare. With Data. At Scale. Cumulative Genotyped Customers (in M, fiscal year ends March 31) 2.0 FY17A 4.4 FY18A 7.8 FY19A 10M+ Genetic Profiles Created Critical Mass 9.8 FY20A ¹As of December 31, 2021. 2As of March 31, 2021. Programs include collaborated, 100% owned and royalty interest targets. 11.3 FY21A 12.2 FY22Q3 Empowering Consumers 12.2M Genotyped Customers¹ Enabling Research & Services 4B+ Phenotypic Data Points² Developing Therapeutics 40+ Programs² Copyright © 2022 23and Me, Inc. 23andMe 11#12Consumer 12.2M Genotyped Customers¹ »»>> Consumer Powered Healthcare Flywheel We run hundreds of billions of association tests per year that further our unique understanding of human biology Data 80% Opt-In to Research Research olli XX Phenotypic Data Genetic Data Insights 1. As of December 31, 2021. 2. As of March 31, 2021. Programs include collaborated, 100% owned and royalty interest targets. 4B+ Phenotypic Data Points¹ Innovative Results Return Value to the Customer Therapeutics / Product Drug Discoveries 40+ Programs² Copyright © 2022 23and Me, Inc. Novel Consumer Products ✔ 23andMe 12#13Ancestry Composition Ancestry Composition East Asian & Native American 51.2% ● Chinese Southeast Asian ● Chinese Vietnamese Indonesian, Thai, Khmer & Myanma Filipino & Austronesian Sub-Saharan African West African Nigerian Ghanaian, Liberian & Sierra Leonean Senegablan & Guinean 47.9% 42.9% 3.0% 9.2% 35.2% 26.5% 14.3% 4.8% Our Ancestry Service A Mass Entry Point to Building a Revolutionary Database Note: Opt-in required for DNA Relatives and Family Tree builder. DNA Relatives DNA Relatives SORT: PERCENT JC LC SC NB VIEW MAP Jocelyn C Mother 50% DNA Shared Leo Cavani Father 50% DNA Shared Sam Cavani 1st Cousin 9.66% DNA Shared Nick Bolton 2nd Cousin 3.69% DNA Shared Visualize Genetic Connections With an Automatically Built Family Tree 23andMe Your Family Tree ? ? Grandparent ? Grandparent ? BM Barbara Miller 2nd Cousin ● HOME Sandra Miller 2nd Cousin 100 Christopher Morris 3rd Cousin 1x removed ANCESTRY ? Mother CK Cory King Brother Jamie King You HEALTH THA PK Philip King Father Cecilia King Sister Copyright © 2022 23and Me, Inc. RESEARCH ? Sam Garfield 3rd Cousin 1x removed Rachel Garfield 3rd Cousin ? Grandfather FAMILY & FRIENDS ? Gertrude King Grandmother 23andMe ? Linda Frank 2nd Cousin 1s removed Susan Martin 2nd Cousin 13#14How Ancestry Matters In Connection To Your Health Current clinical guidelines and eligibility for insurance coverage limit BRCA testing to women with a personal or family history of cancer (Robson, 2003) Ann M. 23andMe Customer Ann did not know her ancestry origins and would not have been eligible for clinical testing under current guidelines. Ann decided to do 23andMe to learn more about her potential health risks. Based on her 23andMe report, she discovered she had a BRCA1 mutation. Her doctor confirmed the results and she opted to have surgeries to reduce her risk of having ovarian and/or breast cancer. ¹ NCCN is the National Comprehensive Cancer Network® (NCCNⓇ). 20% Adult individuals with a BRCA1 or BRCA2 variant Meet NCCNⓇ criteria¹ Identified by healthcare system 50% 80% Missed by healthcare system KKK DTC Testing Do not meet NCCN® criteria 45% 21% 50% KK No first-degree family history of a BRCA-related cancer Did not self-report having Jewish ancestry Copyright © 2022 23and Me, Inc. 23and Me 14#15Health Predispositions 30+ Including: Type 2 Diabetes (Powered by 23andMe Research) Coronary Artery Disease 23andMe+ Uterine Fibroids Migraine 23 and Me+ MUTYH-Associated Polyposis BRCA1/BRCA2 (selected variants) HOXB13 (prostate cancer) Type 2 Diabetes YOUR RESULT Your genetics are associated with a typical likelihood. Based on your DD Genetics Age Our Health Service The First and Only Multi-Disease DTC Genetic Service That Includes FDA-Authorized Reports and Provides Personalized Genetic Insights and Tools 37% H Ethnicity 1 Wellness information does not require FDA Authorization. Wellness¹ 10 Including: Muscle Composition Genetic Weight Alcohol Flush Reaction Saturated Fat and Weight Sleep Movement Dog & Cat Allergies 23andMe+ Genetic Weight YOUR RESULT Your genes predispose you to weigh about 7% less than average. Average 142 lbs Carrier Status 40+ Including: Cystic Fibrosis Sickle Cell Anemia Familial Hyperinsulinism (ABCC8-Related) Tay-Sachs Disease Glycogen Storage Disease (Type 1a) Chromosome 15 Tay-Sachs Disease YOUR RESULT You do not have the variants we tested. (1) 0 variants detected in the HEXA gene Pharmacogenetics 3 Including: SLC01B1 Drug Transport CYP2C19 Drug Metabolism DPYD₂ Drug Metabolism e.g., citalopram and clopidogrel Copyright © 2022 23and Me, Inc. Pharmacogenetics Genetic variants may influence how you process medications. YOUR RESULTS CYP2C19 Drug Metabolism LIKELY NORMAL METABOLIZER DPYD Drug Metabolism LIKELY NORMAL METABOLIZER SLCO1B1 Drug Transport LIKELY NORMAL METABOLIZER 7 FDA Authorizations Print summary 23andMe+ 23andMe 15#16A Meaningful, Engaging (and Fun) Experience Strong Engagement and Trust Drive Longitudinal Data Collection ~80% customers consent to research 4B+ phenotypic data points 180+ published research papers Ice Cream Flavor Preference YOUR RESULT You are more likely to prefer chocolate ice cream. 56% of people with results like yours prefer chocolate ice cream. Neanderthal Ancestry Hey Jaime, You have more Neanderthal DNA than 78% of other customers. Neanderthals were prehistoric humans who interbred with modern humans before disappearing around 40,000 years ago. 16#1723andMe+ Subscription service that offers additional insights and features to give members even more actionable information to live healthier lives Pharmacogenetics 3 reports (FDA-Authorized) Heart Health Reports Atrial Fibrillation, Coronary Artery Disease, LDL Cholesterol, Hypertension DNA Relatives Advanced filters, access up to 5,000 relatives Polygenic Risk Scores (Powered by 23andMe Research) Rapidly discovering new genetic insights: Cancer risk Reproductive Health Diet Sleep Fitness and injuries Migraines Heart Health Learn how your DNA insights can help you care for your heart. LDL 23andMe + Atrial Fibrillation INCREASED LIKELIHOOD Type 2 Diabetes INCREASED LIKELIHOOD 23andMe + Coronary Artery Disease TYPICAL LIKELIHOOD 23andMe + High Blood Pressure TYPICAL LIKELIHOOD 23andMe + LDL Cholesterol TYPICAL LIKELIHOOD#18G 3 Transforming Healthcare with Genetics- Based Primary Healthcare at Scale G T T с T C C с с G#19We Have a Significant Opportunity to Improve People's Health 1. Schroeder, SA. (2007). We Can Do Better - Improving the Health of the American People. NEJM. 357:1221-8. Impact of Different Factors on Risk of Premature Death¹ Social & Environmental Factors 20% Health Care 10% Health and Well-being Individual Behavior 40% Genetics 30%#20Genetic Data Helps Drive Behavior Change ¹ Based on 2019 online survey, designed by 23andMe and M/A/R/C Research, of 1,046 23andMe Health + Ancestry customers. 76% Report taking a positive health action¹ Eat healthier Set future goals to be healthier Adopt a healthier lifestyle in general Exercise more Get more rest / sleep Stop drinking / drink less Stop smoking / smoke less 7% 16% Copyright © 2022 23and Me, Inc. 45% 42% 23andMe 51% 50% 55% 20#21Opportunity for Personalized Healthcare at Scale Practice of Medicine Today Reactive - no customization until symptomatic ¶¶¶¶¶ P 23andMe+ Proactive - truly individualized from the very beginning >> >>> >>> >>> Copyright © 2022 23and Me, Inc. 23andMe 21#22Opportunity to Deliver Genetics-Based Primary Healthcare at Scale X 234 23andMe + len amonaid 1 Health Affairs, "Views Of Primary Care Providers On Testing Patients For Genetic Risks For Common Chronic Diseases." (2018). Genetics-Based Primary Care Diagnostics Testing Pharmacy / E- Prescribing Copyright © 2022 23and Me, Inc. Telehealth Wellness Reports Medical Records 23andMe 22#23What is Genetics-based Primary Healthcare? Health Predispositions Targeted prevention, monitoring, and management Wellness Targeted to help you feel your best Carrier Status Understanding your potential risks Pharmacogenetics Therapeutics that work for you Copyright © 2022 23and Me, Inc. 23andMe 23#2423andMe's Telehealth is Fully Integrated with a Broad Service Offering Online doctor visits Cutting out the doctor waiting room - with fully integrated w-2 core clinical team Mail order pharmacy Cutting out the retail pharmacy - owned and controlled mail order pharmacy ←|→ Broad range of services Building an online healthcare brand with real impact All connected using an algorithm-driven proprietary technology platform Copyright © 2022 23and Me, Inc. 23andMe 24#25G A G The Future: Primary Care Complete Type 2 Diabetes YOUR RESULT Your genetics are associated with a typical likelihood. Based on your XIX Genetics Age 37% (++) Ethnicity Genetic Weight YOUR RESULT Your genes predispose you to weigh about 7% less than average. Average 142 זזזז G Patients will be matched with a doctor who is attuned to genetics, wellness goals, interests, and medical conditions. ● Initial video visit focused on overall health and well being using: Genetics Individual Behavior Wellness Health Care ● Long-term relationship Leading to long, healthy, productive lives Just the beginning! Copyright © 2022 23and Me, Inc. 23andMe 25#26G 4 Transforming Therapeutic Development With the 23andMe Database G T T с T C C T с G#27Limited Use of Genetic Data and Lack of Patient Engagement Constrain Productivity 1. IND Investigational New Drug Application. fdareview.org, "The Drug Development and Approval Process" (2020). 2. Probability of success for a drug to be approved is estimated to be <12%. 3. PhRMA, "Biopharmaceutical Research & Development: The Process Behind New Medicines" (2015). Drug Development is Inefficient 7 years average time-to-IND¹ $2.6B average cost of drug development³ Copyright © 2022 23and Me, Inc. ~90% failure rate2, 3 23andMe 27#28Pharmaceutical Industry 7 years average time-to-IND¹ ~90% failure rate² NATURE GENETICS PUBLICATION 23andMe ~4 years to IND with CD96 drug Targets with genetic evidence have historically had a higher success rate³ The support of human genetic evidence for approved drug indications Nelson et. al 2015 ¹ IND = Investigational New Drug Application. fdareview.org, "The Drug Development and Approval Process" (2020). 2 Probability of success for a drug to be approved is estimated to be <12%. PhRMA, "Biopharmaceutical Research & Development: The Process Behind New Medicines" (2015). 3 Nature Genetics Publication, "The support of human genetic evidence for approved drug indications" (2015). Potential to More Efficiently Develop Novel Therapeutics by "Power, Need, and Speed" 28#29Our Scale Enables Real-Time Genetics Health Research¹ (numbers below represent the number of research participants with the condition indicated) 1,876,573 High cholesterol 1,785,456 Depression 1,113,057 Asthma 634,734 Irritable Bowel 534,696 Arrhythmia 9,047 Systemic Sclerosis 358,275 Type 2 Diabetes 2,355,068 APOE e4 carriers (Alzheimer's risk) 667,019 Eczema 107,126 UC / Crohn's 159,135 Coronary Artery 7,334 Sarcoidosis 37,853 Type 1 Diabetes 85,604 Epilepsy 250,764 Psoriasis 64,800 Barrett's Esophagus 42,836 Pulmonary Embolism 4,528 Idiopathic Pulmonary Fibrosis ¹ As of August 2, 2021. 2 As of September 2021. 3 23andMe COVID-19 manuscript live on MedRXiv September 7, 2020. 1,287,060 COVID-19 study participants 2 COVID-19 Research April 6 March 16 June 8 Sept. 7 750K Consumers participated in the COVID-19 study in the first 90 days (2020) Kicked Off Study Launched Study Preliminary Findings Posted Findings³ Re-contactable Customers Participate in Health Research 29#30Genome-Wide Association Studies (GWAS) GWAS is a statistical analysis of Single Nucleotide Polymorphisms (SNPs), looking To identify differences in frequency between disease cases and controls. SNPs linked with disease will be found at different frequencies in cases versus controls. Association is represented by the level of statistical significance (p-value) of the SNP frequency difference. SNPs can be tested across the genome and mapped to specific regions. Single Nucleotide Polymorphism (SNP) GGCCAGCTGGAGGAGG GGCCAGCTGGAT GAGG - log10 (pvalue) 200- 100- 50 20 5 10 5 2 1 4 102.2 5 6 102.4 7 FLA+ LOD 102.8 8 9 10 11 12 COL CREA Cases 1028 ns11123923 AIRLI CRNI LIBRA M772 SLCOME 14 SCOL 1032 16 TEMI 1034 Copyright © 2022 23and Me, Inc. -80 18 20 22 X Controls 23andMe 30#31Example: Number of Osteoarthritis GWAS¹ hits dramatically increase as database grows 2016 2017 2021 log10 (pvalue) log10(pvalue) log10(pvalue) 12- 10- Size and Scale Accelerate Target Discovery 15- 1 GWAS: Genome-Wide Association Study. 2 3 4 5 6 9 10 11 12 Chromosome 7 8 9 10 11 12 Chromosome 7 8 9 10 11 12 Chromosome 14 14 16 18 20 22 X 16 18 20 22 X 16 18 20 22 X Number of independent hits p<5e-8 New programs are identified through GWAS¹ hits, which increase as size of database grows 40,000 35,000 30,000 25,000 20,000 15,000 10,000 5,000 0 2015 2016 2017 2018 Copyright © 2022 23and Me, Inc. 2019 2020 23andMe 31#32Hundreds of Distinct Clinical Phenotypes Across Major and Rare Diseases musculoskeletal P med brew ww too Telet an Exches tot tactus e bates. tactar act actre TANKTON penal beraatl fora d beck d edh vicepolape cardiovascular wym h pomen www. eyes Phenotyp Morma ver vetur, scho A jele pe pe angle Orthopedic Cardiovascular ___ Ophthalmology Se-Se-New Lost Phenotype NAFLD (Non-Alcoholic Fatty Liver Disease) neurological de ha # spa GRADS de tgk aiskuvend, bebera, k d two un real gastrointestinal end po dericus ded an forhan P C D M metabolic nos storic conte ww by pa wwwww Neurology | tiba mir undirata! G G.I. Metabolic Disease T Cases Controls 48048 2517644 immune Pet ko mweny Cape autoimmune Phenotype aparat our.com. pa hepat nophophag HP dat ut po polymyaltics ...mmg popla ww H words infection Phenotype coram pa Allergy Autoimmunity Infectious Disease THE FREEPLE Hits New Lost 104 44 2 cancer F km.com a gur www.ne ne 23 hood andek HP tomon blood Pastas www.pay www.p sh h te vetbes ret woma good boo bastar www endocrine Phenne lytie m. ey Copyright © 2022 23and Me, Inc. Cancer Hematology Endocrine 42 23andMe ANN cade dedans We haval TREE B . . . . . ܬ ܙ ܕܐ ܚܙܝ 32#3310974910 POLI SARI-2 11 Genetic Association of the TSLP Signalling Pathway With Asthma 34 w3170kb 110 1105 Position on ch5 Mb) 113077426 THE ATSAP TOAL 1₂ Position on a Mb W +RAY Position on chr + CONTRA wwx+ 13 1837253 65 AMA PONED ALDE 0 STANDA 1115 4 ASUT 80 TSLPR Cell membrane JAK2 TSLP STAT5 JAK1 Proinflammatory signaling IL-7Ra I T 1 I CHOP 2 -PARC -OHOO 12607352 DAMA T scie Postion on M 12409003 # Ma JANY 849 65 Position on chrt (Mal +1000+CHUN X+ +6241 59° ° ° °CAT 2522 496016. E AARSON NOR -Dw THEN 35.9 WASI NAU HILD compre PANCO rung --00734 MERI RAPPEL TREGON 425 Poction on 17 M 65.1 inge MUNDO Maje COMO WEN an 30 65.2 cocass - AFLAD 43.5 229 2 TSLP is a well-known cytokine with a role in maintaining immune homeostasis and regulating inflammatory responses at mucosal barriers. The TSLP signaling pathway is an attractive therapeutic target. e.g. Tezepelumab, a TSLP-blocking monoclonal antibody for treatment of asthma. Our genetic data shows that multiple genes within the TSLP pathway associate strongly with asthma. Copyright © 2022 23and Me, Inc. 23andMe 33#34Breadth of Phenotyping Provides Deeper Genetic Understanding Beyond Single Diseases PheWAS = Phenotype Wide Association Study Every SNP in the genome can be interrogated at >1,000 medically related phenotypes. Besides the role of a gene in a disease of interest, we can use genetics to learn potential indication expansions or possible unwanted toxicities. For TSLP, PheWAS indicates lack of effect in eczema but also highlights potential indication expansion in a rare disease. TSLP PheWAS Asthma - crohns - eczema. hashimotos - multiple sclerosis - psoriasis- psoriatic_arthritis. Rare disease A- rhinitis. tid. ulcerative colitis - TSLP GWAS signal 2 TSLP GWAS signal 3 TSLP GWAS signal 1 Copyright © 2022 23and Me, Inc. log(OR) 0.2 0.0 -0.2 23andMe 34#35>>> >>> >>> >>> Systematic, Scalable Research Platform Yields Novel Drug Targets Phenotypic Data Genetic Data 10,000s of Genome-Wide Association Study (GWAS) Hits Determine Disease Associated Genes and Directionality Translational Research to Understand Mechanism Identifying Druggable Targets Phenome-Wide Association Studies (PheWAS) Reveal Additional Indications and Potential Safety Concerns Assessment of Unmet Need and Competitive Landscape Best Drug Targets Wet lab validated targets progress through standard stages of research toward the selection of preclinical lead molecules and clinical development 23andMe's database yields thousands of GWAS hits Advanced biology and medicinal chemistry guide design of optimal compounds from initial targets Phenotypic breadth provides unique ability to uncover potential safety issues or possible indication expansions Copyright © 2022 23and Me, Inc. 23and Me 35#36We Have Generated a Research and Development Pipeline Covering Multiple Therapeutic Areas Immuno-oncology GSK'608 (CD96) EARLY-STAGE THERAPEUTIC AREAS (multiple programs in each area) Immuno-oncology Immunology 23ME'610 (CD200R1) Cardiovascular/ Metabolic Neurology Discovery Preclinical Phase 1 140+ programs in the combined therapeutic areas. Programs include collaborated, 100% owned and royalty interest targets. Note: As of March 31, 2021 40+ programs¹ gsk 23andMe Phase 2 Copyright © 2022 23and Me, Inc. Next Milestone Phase 1 Data Phase 1 Data 23andMe 36#37GSK'608 Targeting CD96#38Our Lead CD96 Program Was Identified With ML and AI Applied to Our Proprietary I/O Genetic Signature Large I/O market with over $41B expected in 2021 sales 2021 projected sales of leading checkpoint inhibitors KEYTRUDA $17.0B OPDIVO YERVOY $7.9B $1.8B CD96 axis validated with ML and AI applied to our proprietary I/O genetic signature which also identifies marketed I/O drugs Source: Evaluate Pharma historical and forecast estimates. I/O genetic signature shows opposing effects on autoimmune and cancer phenotypes tonsillectomy 11d- anti tn alpha or dmards- juvenile 11d- iqb.dry skin frequency lodine treatment ever hypothyroidism- hyperthyroidism- hashimotos- graves vitigo- iqb.dandruff frequency" celiac HLA al- psoriasis rheumatoid arthritis- look meds anti inf alpha- thyroid removed- immunodeficiency- squamous cell carcinoma- basal cell carcinoma actinic keratosis non melanoma skin cancer- any skin cancer- Autoimmune Cancer We discovered the signaling pathway has a similar genetic I/O signature CD96 plays an important role in regulating NK and T cell antitumor activity APC/Tumor cell GSK 608 T cell/NK cell CD96 Copyright © 2022 23and Me, Inc. + CD155 CD226 ITIM GSK'608 (anti-CD96) is progressing through a Phase 1 multiple-ascending dose trial in patients with advanced solid tumors 23and Me TIGIT 38#39PD-1, CD96 and TIGIT are Negative Regulators of CD226 Axis Combining inhibitors may enhance anti-cancer activity - Activating/co-stimulatory interaction - Inhibitory interaction CD112 PVRIG APC/Tumor TIGIT CD155 PD-L1 CD226 CD96 PD-1 T/NK cell ● ● CD226 activates NK/T-cells PD1 directly regulates CD226 activity TIGIT and CD96 indirectly suppress CD226 Combining inhibitors (anti- PD-1, anti-CD96, anti-TIGIT) may have more activity that anti-PD-1 alone Copyright © 2022 23and Me, Inc. 23andMe 39#40Preclinical Data Supports Combining CD96 with PD-1 and TIGIT Inhibitors CD96, TIGIT and PD-1 Combination Suggests Synergy Mean tumor size (mm²) 200- 150- 100- 50- 0 0 clg aCD96- BαPD1 A&TIGIT (G2a)- aCD96 + aTIGIT (G2a) CPD1 + aCD96 *aPD1 + αTIGIT (G2a) e aPD1 + @TIGIT (G2a) + aCD96 5 10 15 20 25 30 35 40 45 50 Days after CT26 tumor inoculation Cancer Immunol Res. 2019;7(4):559 55 Anti-CD96 + Anti-TIGIT+ Anti-PD1 Combination CD226 axis components owned by GSK Component Molecule PD-1 CD96 PVRIG TIGIT Dostarlimab GSK'608 SRF813 GSK4428859 (EOS448) Partner Acquired from Tesaro 23andMe In-license from Surface Oncology iTeos Copyright © 2022 23and Me, Inc. 23andMe 40#41Phase 1 Study Design for GSK6097608 (GSK'608): A High Affinity Monoclonal Antibody Against CD96 Study Design Phase 1 Study population: * Locally advanced, recurrent, or metastatic solid tumors Nonrandomized * Progressed after, intolerant of, or inappropriate for standard therapy Open label Escalating doses of GSK6097608 Q3W 0 000 Sequential assignment Arm A (GSK6097608) Escalating doses of GSK6097608 Q3W + fixed dose of dostarlimab Q3W Multicenter RP2D determined Enrollment in arm B begins once a dose of GSK6097608 from arm A has been identified based on safety and PK/PD data Enrollment in PK/PD cohort Arm B (GSK6097608 + dostarlimab) RP2D determined Enrollment in PK/PD cohort https://www.clinical trials.gov/ct2/show/NCT04446351 ADA, anti-drug antibodies; AEs, adverse events; ORR, objective response rate; PK, pharmacokinetics; PK/PD, pharmacokinetics/pharmacodynamics; Q3W, every 3 weeks; RP2D, recommended Phase 2 dose Study Endpoints Primary Secondary - Dose limiting toxicities *Adverse events * ORR per RECIST 1.1 - ADAs against GSK6097608 and dostarlimab - PK parameters of GSK6097608 and dostarlimab Strategic Collaboration with gsk Current Status The study is currently open and recruiting. . Serious adverse events . Clinically important changes in laboratory parameters, electrocardiograms, and vital signs • Dose reductions or delay • Withdrawal due to AES Commenced in 2020; data expected 2022 Copyright © 2022 23and Me, Inc. OPEN 23andMe 41#42GSK'608 Targeting CD96: A Genetically- Validated Approach to Anti-Cancer Therapy Partnered with gsk CD96 is Part of the genetically-validated CD226 axis that is associated with cancer and autoimmunity Inhibition of CD96 leads to immune activation and tumor growth inhibition in non-clinical models GSK6097608 (GSK’608) is a high affinity monoclonal antibody against CD96 Further clinical development will focus on extending the benefit of GSK'608 in combination with other I/O therapies Phase 1 data for GSK6097608 is anticipated in 2022 Copyright © 2022 23and Me, Inc. 23andMe 42#4323ME'610 Targeting CD200R1#44CD200R1 was Identified as a Promising Anti-Cancer Drug Target with 23andMe's Proprietary Immuno-oncology (I/O) Genetic Signature Immune and autoimmune phenotypes Cancer phenotypes Identified novel immuno-oncology signature around CTLA4. tonsillectomy - 11d- anti tnf_alpha_or_dmards - juvenile_t1d- iqb.dry_skin_frequency - iodine treatment_ever- hypothyroidism - hyperthyroidism - hashimotos - graves - vitiligo- iqb.dandruff frequency- celiac HLA all- psoriasis- rheumatoid arthritis - took_meds_anti_tnf_alpha- signed log(p) thyroid_removed - immunodeficiency- squamous_cell_carcinoma - basal cell carcinoma - actinic_keratosis - non_melanoma_skin_cancer any_skin_cancer- -10 -5 0 5 10 Genetic Variant in CTLA4 linked with multiple phenotypes in the 23andMe database CD200R1 pathway identified as a critical immune checkpoint with our I/O genetic signature CD200R1 Receptor թսոաալ I/O genetic signature shows opposing effects on autoimmune and cancer phenotypes Cancer Cancer Immune CD200 Ligand DOK2 Protein Immune Cancer signed log(p) -10 -5 0 5 10 We discovered that 3 components of the signaling pathway for CD200R1 have a similar genetic signature to other I/O drugs Copyright © 2022 23and Me, Inc. 23and Me 44#45CD200R1 is an Immune Checkpoint CD200R1 is an inhibitory receptor expressed on T-cells and myeloid cells CD200 is the only known ligand for CD200R1 in humans and is highly expressed in certain cancers Binding of CD200 to C200R1 decreases the ability of T-cells to recognize and kill cancer cells Several viruses have co-opted CD200 analogues to suppress and evade the host immune response References: J Virol 2012;86:6246, J Virol 2004;78:7667, J Immunol 2005;175:4441, Structure 2013;21:820, JCI Insight 2018;3:e96836 CD200:CD200R1 Signaling Tumor cell Reduced Anti-Tumor Immune Response CD200 Dok2 Copyright © 2022 23and Me, Inc. CD200R1 RasGAP ERK T-cell Ras 23andMe 45#4623ME-00610 (23ME'610) Binds with High Affinity to CD200R1 and Inhibits Immunosuppressive Signaling 23ME '610 is a fully humanized, effectorless, IgG1 antibody against human CD200R1 23ME '610 binds CD200R1 with high affinity (K₁ < 0.1 nM) 23ME '610 blocks CD200 ligand binding to CD200R1, resulting in inhibition of immunosuppressive signaling The restoration of T-cell activity by 23ME '610 was demonstrated using in vitro models of the tumor microenvironment No adverse effects of blocking CD200R1 have been observed in nonclinical toxicology studies 23ME'610 Activates T-cell Function by Blocking the CD200R1 Checkpoint Tumor Cell CD200 CD200R1 CD8+ T Cell + Suppressed T cell function Copyright © 2022 23and Me, Inc. Tumor Cell 23ME-00610 CD8+ T Cell ↓ Activated T cell 23andMe 46#47Phase 1 Study of 23ME'610 in Patients with Locally Advanced or Metastatic Solid Malignancies 1 Phase 1 Patients with locally advanced, unresectable or metastatic solid tumors that have progressed after or are inappropriate for standard therapy Study Design Y Openlabel Non- Randomized Part A (n = 26) Monotherapy Dose Escalation (IV Infusion Q3W) Accelerated Titration 3+3 Cohorts x RP2D / MTD Multi-center Part B (n = 75) Expansion Cohort Expansion Cohort Expansion Cohort Expansion Cohort Expansion Cohort Primary Objectives Part A: Safety (DLTS, AES) Part B: Efficacy (ORR) Secondary and Exploratory Efficacy (ORR [RECIST and iRECIST]), DOR, PFS, OS) and Safety Pharmacokinetics Pharmacodynamic biomarkers Abbreviations: AEs: Adverse Events; DLT: Dose limiting toxicity; DOR: duration of response; IV: intravenous; ORR: Objective Response Rate; OS: Overall Survival; PFS: Progression Free Survival; Q3W: every three weeks; RECIST: Response Evaluation Criteria in Solid Tumors; RP2D: Recommended Phase 2 Dose Copyright © 2022 23and Me, Inc. 23andMe 47#4823ME'610 Targeting CD200R1: A Genetically-Validated Approach to Anti-Cancer Therapy >>> CD200R1 is an immune checkpoint with a strong I/O signature in three components of the pathway CD200 is highly expressed in a subset of human cancers and its binding to CD200R1 decreases the ability of T cells to recognize and kill cancer cells 23ME'610 is a potent, effectorless, monoclonal antibody against CD200R1 that has the potential to restore T-cell killing of cancer cells >>> The Phase 1 dose escalation study of 23ME'610 in patients with advanced solid malignancies was initiated in January 2022 Further evaluation of 23ME'610 will occur in expansion cohorts for adolescents and for specific disease areas#49G G 5 Financials T с T C C с G#501 2 Strong Financial Foundation to Invest in Future Growth Potential Investing in future growth potential. Integrating TeleHealth into consumer business plus increased spending on Therapeutics R&D by 34% in YTD'22 compared to the same period in the prior year Growing consumer services and genetic / phenotypic database. Balancing growth with profitability in Consumer and Research Services supports additional investment in Therapeutics' efforts 3 Strong cash position. Cash of $586 million¹ supports 23andMe's plans for significant investment in Therapeutics portfolio and strategic initiatives ¹As of December 31, 2021. Copyright © 2022 23and Me, Inc. 23andMe 50#51Strategic Investments in Future Growth Potential FY2022 Guidance* (updated 2/10/22) Revenue $268 to $278 million Adjusted EBITDA -$148 to -$163 million Net Loss -$205 to -$220 million *Financial year ends March 31, 2022#52(in $M) Revenue Cost of Revenue Gross Profit R&D S&M G&A Total Operating Expenses Income Statement and FY2022 Guidance Loss from Operations Interest and Other (Expense) Income Loss before Benefit for Income Taxes Benefit for Income Taxes Net Loss Note: Fiscal year ends March 31. Nine Months Ended December 31, FY2022 Amount $171 85 86 139 71 61 271 (185) 33 (152) 4 ($148) FY2021 Amount $155 83 72 114 31 46 191 (119) 2 (117) ($117) Year Ended March 31, FY2022 Guidance Amount $268 - $278 N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A ($220) - ($205) FY2021 Amount $244 127 117 160 43 99 302 H (185) 1 (184) ($184)#53(in $M, except percentages) Consumer Services Research Services Therapeutics Total Revenue Amount $138 33 $171 Revenue Composition Nine Months Ended December 31, FY2022 Percentage of Revenue 81% 19% 100% Amount $119 36 O $155 FY2021 Percentage of Revenue 77% 23% 0% 100% Year Ended March 31, Amount $198 46 O $244 FY2021 Copyright © 2022 23and Me, Inc. Percentage of Revenue 81% 19% 0% 100% 23andMe 53#54Consumer Services Revenue Seasonality by Quarter FY 2019 FY 2020 FY 2021 Note: Fiscal year ends March 31. Q1 28% 24% 18% Q2 19% 24% 21% Q3 18% 21% 22% Q4 35% 31% 39% Copyright © 2022 23and Me, Inc. Full Year 100% 100% 100% 23andMe 54#55(in $M, except percentages) Therapeutics Research and Development Expense Consumer and Research Services Total R&D Expense Amount $66 73 $139 Nine Months Ended December 31, FY2022 Percentage of total R&D expense 47% 53% Amount $49 65 $114 FY2021 Percentage of total R&D expense 43% 57% YoY Copyright © 2022 23and Me, Inc. % Change 34% KK 12% Investing in Therapeutics <<< 23andMe 55#56Sales and Marketing Expense Composition (in $M) Advertising and Brand Personnel-related expenses Outside Services, equipment and supplies Depreciation and Amortization Facilities and other OH Alloc Total S&M Expense Note: Balances may not add up due to rounding Nine Months Ended December 31, FY2022 Amount $48 10 4 2 6 $71 FY2021 Amount $11 11 4 6 $31 Copyright © 2022 23and Me, Inc. 23and Me 56#57Segment Information and Reconciliation of Non-GAAP Financial Measures Note: Fiscal year ends March 31. (unaudited) (in $K) Segment Revenue Consumer & Research Services Therapeutic Total Revenue Segment Adjusted EBITDA Consumer & Research Services Therapeutics Unallocated Corporate Total Adjusted EBITDA Reconciliation of Net Loss to Adjusted EBITDA Net Loss Adjustments: Interest (income), net Other (income) expense, net Change in fair value of warrant liabilities Income tax benefit Depreciation and amortization Amortization of acquired intangible assets Stock-based compensation expense Acquisition-related costs Total Adjusted EBITDA Nine Months Ended December 31, FY2022 Amount $171,334 $171,334 ($33,232) (57,046) (30,692) ($120,970) ($147,946) (213) (39) (32,989) (3,512) 14,188 2,898 37,473 9,170 ($120,970) FY2021 Amount $155,290 $48 $155,338 ($4,925) (38,886) (21,554) ($65,365) ($116,606) (195) (1,318) 15,532 37,222 ($65,365)#58Reconciliation of GAAP Net Income Outlook to Non-GAAP Adjusted EBITDA Outlook Note: Fiscal year ends March 31. (unaudited) (in $K) Reconciliation of Net Loss to Adjusted EBITDA Net Loss Adjustments: Interest (income), net Other (income) expense, net Change in fair value of warrant liabilities Income tax benefit Depreciation and amortization Amortization of acquired intangible assets Stock-based compensation expense Acquisition-related costs Total Adjusted EBITDA Outlook for the Year Ending March 31, 2022 Low Amount ($220,000) (285) (174) (32,989) (3,505) 19,712 7,246 57,794 9,168 ($163,033) High Amount ($205,000) (285) (174) (32,989) (3,505) 19,712 7,246 57,794 9,168 ($148,033) Copyright © 2022 23and Me, Inc. 23and Me 58#59We Are Redefining Healthcare. With Data. At Scale. Empowering Consumers 12.2M Genotyped Customers¹ Enabling Research & Services 4B+ Phenotypic Data Points¹ Developing Therapeutics 40+ Programs² ¹As of December 31, 2021. 2As of March 31, 2021. Programs include collaborated, 100% owned and royalty interest targets. Genetics-based Primary Care Coming Soon FDA Authorized 7 FDA Authorizations Strong Cash Position $586M¹ Copyright © 2022 23and Me, Inc. 23andMe 59#60G G Appendix T с T C C с G#61The Vast Majority of GWAS Discoveries Can be Made Without Large-scale Sequencing Nearby genetic variants are correlated with each other. Knowing the variant in one position allows nearby variants to be inferred. E.g. Fill in the blanks: The q***k brown f*x jumps ov*r the **zy dog. The same principle applies in genetics. The process of filling in the gaps is known as 'genotype imputation'. We type ~650,000 SNPs using our genotyping array, which allows accurate imputation for >35m SNPs in the genome. Genotype imputation is much more cost effective than large- scale sequencing. • Whole-genome sequencing -$1000/sample. Exome sequencing ~$400 / sample. Imputation < $0.01/ sample We do deploy sequencing in situations where there is a clear benefit over and above imputation (e.g. rare disease). Genotyped Samples 21 022?? 2 0 1 12 22 2 010 2 071227 22 011?? 2 0 17221212 120 2 0 27272727121 270 121212121 222 22 0 1 07272727021772 21 1 101 2 1 1 0 0 222 -logiolp-value) -log/p-value) 20 15- o 5 0 20- 15 5 0 2 1 2 0 176.3 go 176.4 0010111001111110 1 1 1 1 1 1 1 0 0 1 0 0 1 1 1 0 1 1 1 1 1 0 1 0 0 1 0 0 0 1 0 1 0 0 0 0 1 1 1 0 0 1 1 1 1 1 10 1110110 011101 110 0010111001111110 1111101001000101 1 1 0 0 0 1 0 0 1 1 1 0 1 1 1 0 rs2011077 rs1966265 Reference Genomes Imputation Process 0?1? 11 1701 ?1? 0 1 2 1 2 1 2 1 2011 ? ? 120 176.5 0 0.00 88 A 1 2 1 2 1 2 1 7 0 1 0 ? ? 1? 0 1?1?1?1? 111 ??1? 0 1202020?111 ? ? 120 0?1?0?0?111? ? 120 008 0 0 0 0 0 %0° 176.6. 176.7 Position on chr5 (Mb) 176.8 Copyright © 2022 23and Me, Inc. 176.9 Imputed Samples 1 2 1 10022 1 102220010 2 0 2 1 0 112220011 2 0 11201110120122 0 2222212012112220 1110121012212220 0121212002111211 2221111 101 1210020 222 177 2 1 2 0 Before imputation After imputation 23andMe 61#62Strategic Collaboration With gsk $300M equity investment 50/50 shared costs and profits Access to GSK technology and platforms "Our work with 23andMe is exceeding expectations and helping us advance a new way of thinking about drug discovery, one driven by genetics and the DNA we inherit. The insights of why some people are protected from or are at greater risk for certain diseases can lead to genetically validated targets that are at least twice as successful in clinical trials." Dr. Hal Barron, Chief Scientific Officer & President R&D, GSK (2021)#631 23andMe's Value Proposition Disrupting the Healthcare experience. 23andMe is building a personalized health and wellness experience that caters uniquely to the individual by harnessing the power of their DNA. Integrating Lemonaid Health's online digital health platform to deliver personalized, prevention-oriented, genetically- based healthcare at scale The world's premier re-contactable phenotype-linked genetic database. A vast (>12M genotyped 2 customers) proprietary dataset rich with both genotypic and phenotypic (health) information allows insights that unlock revenue streams across digital health, therapeutics, and much more Continuously increasing quantity and quality of phenotypic data. Impressive customer participation 3 provides >4 billion phenotypic data points for unprecedented statistical power to discover new insights into health and potential therapies. Over 40 identified therapeutics programs validates the approach of developing novel therapeutics 4 using genetic data. One program in clinical development with GSK, one wholly owned program started clinical trials in January 2022. Difficult to replicate platform for value creation. The FDA-approved consumer platform, the 5 therapeutics efforts, and the rich database combine to create multiple opportunities for substantial value creation 6 Strong cash position. Strong balance sheet supports 23and Me's plans for significant investment in therapeutics portfolio and strategic initiatives Copyright © 2022 23and Me, Inc. 23andMe 63